The present invention relates generally to an intravascular implant and methods of using the implant within the vasculature of the body, particularly adjacent to vascular aneurysms. The present invention also relates to the attachment of a second implant, such as a vascular graft, to the intravascular implant.
An aneurysm is an abnormal dilatation of a biological vessel. Aneurysms can alter flow through the affected vessel and often decrease the strength of the vessel wall, thereby increasing the vessel's risk of rupturing at the point of dilation or weakening. Implanting a vascular prosthesis through the vessel with the aneurysm is a common aneurysm therapy. Vascular grafts and stent grafts (e.g., ANEURX® Stent Graft System from Medtronic AVE, Inc., Santa Rosa, Calif.) are examples of vascular prostheses used to treat aneurysms by reconstructing the damaged vessel.
Stent grafts rely on a secure attachment to the proximal, or upstream, neck of an aneurysm, particularly for aortic abdominal aneurysms (AAA), but several factors can interfere with this attachment. The proximal neck of the aneurysm can be diseased. This diseased tissue can by a calcified and/or irregularly shaped tissue surface for which the graft must to attach. Healthy, easily-attachable tissue is often a distance away from the aneurysm. For example, in AAAs the nearest healthy vascular tissue may be above the renal arteries. Even a healthy vessel can be so irregularly shaped or tortuous that a graft may have difficulty attaching and staying sealed. Furthermore, the proximal neck can shift locations and geometries over time, particularly over the course of aneurysm treatment and reformation of the aneurysmal sack. This shifting and shape changing of the vessel can result in partial or total dislodgement of the proximal end of a currently available stent graft.
Devices have been developed that attempt to solve the issue of vascular graft attachment. International Publication No. WO 00/69367 by Strecker discloses an aneurysm stent. The stent has a securing mechanism that attaches to the vascular wall proximal to the renal arteries, which is typically where healthier vascular tissue is located when a patient has an AAA. The stent also has a membrane that is placed at the proximal end of a stent graft and forms a seal in the vessel. Strecker, however, discloses a securing mechanism with ball-ended struts which angle away from the seal. The ball-ends will reduce the pressure applied by the struts onto the vascular wall, and the struts are angled improperly to insure the best anchor. If the graft begins to dislodge into the aneurysm, the struts will tend to fold inward and slide with the graft instead of engaging frictionally into the vascular walls to prevent dislodgement.
U.S. Pat. No. 6,152,956 to Pierce discloses a radially expandable collar connected by connecting wires to an expandable stent. The stent also has barbs with sharp ends that spring radially outward to embed into the walls of the vascular tissue. The stent, however, is expandable, but once expanded cannot be easily contracted. The stent, therefore, can not be repositioned if incorrectly placed during initial deployment. Further, the barbs do not angle toward the seal and will not engage into the vascular wall for additional anchoring force, should the prosthesis begin to become dislodged.
U.S. Pat. No. 6,361,556 by Chuter discloses a stent for attaching to grafts, where the stent is connected to an attachment system for anchoring to the vessel. The attaching system has hooks angled toward the graft. The attachment system has no way of being repositioned during deployment. Further, the stent is a substantially rigid, balloon expandable stent and therefore maintains a fixed diameter and resists deformation from forces imposed by the vascular environment. The stent, therefore, can not be easily repositioned during deployment and may not seal the graft under changing geometric conditions over time.
There is thus a need for a device and method that can securely anchor a vascular graft within a vessel and can seal the graft regardless of the existence of diseased tissue at the sealing location. There is also a need for a device that can be deployed to the vasculature while minimizing bloodflow obstruction to the main vessel and to branching vessels. A need also exists for a device and method that can accomplish the above needs and adjust to tortuous vasculature. There is also a need for a device and method that can accomplish the above and have dimensions and a placement location that can be adjusted multiple times in vivo, even after the anchor has been fully deployed. There is also a need for a device that can be delivered through a low profile catheter. Additionally, there is a need for a device that can anchor into a different portion of tissue from which it seals, so as not to overstress any individual portion of vascular tissue or any elements of the implant, thus preventing fractures in the tissue and of the implant.
One embodiment of the disclosed intravascular implant has a seal, a connector, and an anchor. The seal is configured to attach to a second implant. The connector has a first end and a second end. The first end is attached to the seal, and the second end is attached to the anchor. The anchor has an arm, and the arm is angled toward the seal as the arm extends radially away from the center of the anchor. The anchor can be formed of multiple radially extending tines or arms such as an uncovered umbrella structure, a hook and/or a barb.
Another embodiment of the disclosed intravascular implant has a seal and a substantially cylindrical coil, where the coil is attached to, and extends from, the seal. The seal can also have a gasket. The seal can also have an inflatable collar.
Yet another embodiment of the intravascular implant has a seal, a connector and an anchor. The seal is configured to attach to a second implant. The connector has a first end and a second end and may be flexible. The first end is attached to the seal, and the second end is attached to the anchor. The connector may be formed of a coil. The connector can be configured to allow for longitudinal adjustments. The distance between the seal and the anchor can be changed. The implant can also have a second anchor to assist in additional fixation.
Another embodiment of the intravascular implant has a seal, a connector, an anchor, and a stop. The connector has a first end and a second end. The first end is attached to the seal, and the second end is attached to the anchor. The anchor has an arm and the arm is angled toward the seal as the arm extends radially from the center of the anchor. Radial extension of the arm is limited by the stop. The stop can be a mechanical interference.
Yet another embodiment of the disclosed intravascular implant has a seal, a connector and an anchor. The connector has a flexible member, a first end and a second end. The first end is attached to the seal and the second end is attached to the anchor. The anchor has an arm. The arm angles toward the seal as the arm extends radially from the center of the anchor. The seal can have a gasket. The seal can have an inflatable collar. The connector can have a coil. The implant can also have a second anchor.
The second end 8 can be attached to a seal 20. The second end 8 can attach to the seal 20 through an attachment device 22, for example struts. The attachment device 22 can be integral with the second end 8, integral with the seal 20, or an independent part. Attachment devices 22 can also be used to attach the connector 4 to the anchor 10. The seal 20 can have a first proximal end 24 and a first distal end 26. A second implant 28 can be attached to the seal 20, for example at the distal end 26, or the second implant 28 can be an integral part of the seal 20.
The seal 20 can have a first seal cover 34 attached at the proximal end 24 to the first seal ring 30 and at the distal end 26 to the second seal ring 32. The seal cover 34 can be made from polymers such as polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE, ePTFE, PEEK, nylon, polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), polyglycolic acid (PGA), polyurethane, polyethylene, vascular, valvular or pericardial tissue, extruded collagen, silicone, metal mesh, radiopaque materials, or any combination thereof.
A seal flow port 36 can be the hole defined by the inner radii of the seal rings 30 and 32 and the seal cover 34. The seal 20 can have a seal diameter 38 that can depend on the diameter of the vessel in a given patient. The seal diameter 38 can be from about 5 mm (0.2 in.) to about 50 mm (2.0 in.), for example about 30 mm (1.2 in.). The seal 20 can have a seal height 40 from about 1 mm (0.04 in.) to about 6 cm (2.4 in.).
A first and/or second seal flow ports 62 and 64, respectively, can be defined, for example as cylinders, within the seal volume 60. Once deployed, multiple seal flow ports 62 and 64 can attach to multiple second implants 28, or multiple legs of the second implant 28 that can extend distal of the seal into the iliac arteries. A connector port 66 can also be defined, for example as a cylinder, within the seal volume 60. The second end 8 of the connector 4 can be placed into the connector port 66. The seal volume 60 can be inflated after the second end 8 is placed into the connector port 66 to constrict and pressure fit the connector port 66 around the second end 8, thereby fixedly attaching the seal 20 to the connector 4.
A first hub 76 can be fixedly attached or rotatably attached to first seal struts 78 and a center beam 80. The first seal struts 78 can slidably connect on the outside or inside of the first seal ring 30 at free points 82. The first seal struts 78 can be fixedly or rotatably attached to the second seal ring 32 at fixation points 84. The first seal struts 78 can be fixedly attached or rotatably attached to a first collar 86. The first collar 86 can be slidably attached to the center beam 80.
A second hub 88 can be fixedly attached or rotatably attached to second seal struts 90 and the center beam 80. The second seal struts 90 can slidably connect on the outside or inside of the second seal ring 32 at the free points 82. The second seal struts 90 can be fixedly or rotatably attached to the first seal ring 30 at the fixation points 84. The second seal struts 90 can be fixedly attached or rotatably attached to a second collar 92. The second collar 86 can be slidably attached to the center beam 80. The seal struts 78 and 90, the hubs 76 and 88, and the collars 86 and 92 can be from the same materials as the seal rings 30, 32 and 52.
The seal rings 30 and 32 can be wave-shaped.
The attachment devices 22 can be wires, coils, rods or combinations thereof. The connector 4 can also be directly attached to the seal 20. The connector 4 can be attached to the attachment devices 22 at a connector interface 116. The connector interface 116 can have a hub, slider, or collar. The connector interface 116 can be a direct attachment. The connector 4 and attachment device 22 can also be an integral part. The seal 20 and attachment device 22 can also be an integral part.
Methods of Manufacture
The tissue mainstays 33, shown in
As shown in
Integrated parts can be made from pre-formed resilient materials, for example resilient alloys (e.g., Nitinol, ELGILOY®) that are preformed and biased into the post-deployment shape and then compressed into the deployment shape.
Any elongated parts used in the intravascular implant 2 and the second implant 28, for example the tip 12, the arms 14, the leafs 16, the attachment devices 22, the seal rings 30, 32 and 52, the seal coil 68, the connector coil 118, the connector rod 120, the connector strut 124, the anchor coil 134 and the arm supports 152, can be ovalized, or have an oval cross section where necessary, to ease crimping with other parts.
Method of Use
The intravascular implant 2 can be collapsed or compressed into a deployment configuration to enable minimally invasive implantation into the vasculature of a patient.
The intravascular implant 2 can be loaded into a delivery catheter 168 by methods known to those having ordinary skill in the art. Because the design of the intravascular implant 2 can separate the anchor 10 from the seal 20, a low profile catheter can be used to deliver the intravascular implant 2. As illustrated in
As illustrated in
As illustrated in
The arms 14 and/or the seal 20 can apply chronic stress to the adjacent tissue in the vascular site 170 causing a controlled migration of the arms 14 and/or seal 20 into the wall of the vascular site 170 to a specified depth predetermined by the tissue mainstays 33 and/or 148. The predetermined depth can be the length of the tissue mainstay 33 and/or 148, or a force exerted by the tissue mainstay 33 and/or 148. The controlled migration is then halted by either a distribution of force along the greater surface area between the tissue mainstay 33 and/or 148 and the wall of the vascular site 170 or the diminishing force on the same surface area once the radially central end (with respect to the anchor 10) of the tissue mainstay 33 and/or 148 has reached the wall of the vascular site 170, or a combination of both. Tissue can then ingrow around the tissue mainstay 33 and/or 148 providing a biologic seal or anchor so that the integrity of the seal or anchor is not purely mechanical.
It is apparent to one having ordinary skill in the art that various changes and modifications can be made to this disclosure, and equivalents employed, without departing from the spirit and scope of the invention. Elements shown with any embodiment are exemplary for the specific embodiment and can be used on other embodiments within this disclosure.
This application is a continuation of U.S. patent application Ser. No. 15/284,381 filed Oct. 3, 2016, which is a continuation of U.S. patent application Ser. No. 13/666,756 filed Nov. 1, 2012 (now U.S. Pat. No. 9,615,912), which is a continuation of U.S. patent application Ser. No. 11/351,423 filed Feb. 10, 2006 (now abandoned), which is a continuation of U.S. patent application Ser. No. 10/778,870 filed Feb. 12, 2004 (now abandoned), which claims the benefit of U.S. Provisional Application No. 60/447,056 filed Feb. 12, 2003, the contents of all which are incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
2903365 | O'Brian et al. | Sep 1959 | A |
3834394 | Hunter et al. | Sep 1974 | A |
4085757 | Pevsner | Apr 1978 | A |
4108173 | Silvenko | Aug 1978 | A |
4301803 | Handa et al. | Nov 1981 | A |
4341218 | U | Jul 1982 | A |
4346712 | Handa et al. | Aug 1982 | A |
4553545 | Maass et al. | Nov 1985 | A |
4577631 | Kreamer | Mar 1986 | A |
4638803 | Rand | Jan 1987 | A |
4641653 | Rockey | Feb 1987 | A |
4728328 | Hughes et al. | Mar 1988 | A |
4944745 | Sogard et al. | Jul 1990 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
5078726 | Kreamer | Jan 1992 | A |
5104404 | Wolff | Apr 1992 | A |
5133731 | Butler et al. | Jul 1992 | A |
5151105 | Kwan-Gett | Sep 1992 | A |
5156620 | Pigott | Oct 1992 | A |
5163953 | Vince | Nov 1992 | A |
5181921 | Makita et al. | Jan 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5226911 | Chee et al. | Jul 1993 | A |
5282824 | Gianturco | Feb 1994 | A |
5308356 | Blackshear, Jr. et al. | May 1994 | A |
5312415 | Palermo | May 1994 | A |
5330528 | Lazim | Jul 1994 | A |
5334217 | Das | Aug 1994 | A |
5360443 | Barone et al. | Nov 1994 | A |
5395333 | Brill | Mar 1995 | A |
5411550 | Herweck et al. | May 1995 | A |
5478309 | Sweezer et al. | Dec 1995 | A |
5534024 | Rogers et al. | Jul 1996 | A |
5540711 | Kieturakis et al. | Jul 1996 | A |
5558642 | Schweich, Jr. et al. | Sep 1996 | A |
5575817 | Martin | Nov 1996 | A |
5578071 | Parodi | Nov 1996 | A |
5582619 | Ken | Dec 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5593442 | Klein | Jan 1997 | A |
5613981 | Boyle et al. | Mar 1997 | A |
5628783 | Quiachon et al. | May 1997 | A |
5665117 | Rhodes | Sep 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5693088 | Lazarus | Dec 1997 | A |
5702361 | Evans et al. | Dec 1997 | A |
5704910 | Humes | Jan 1998 | A |
5713917 | Leonhardt et al. | Feb 1998 | A |
5725568 | Hastings | Mar 1998 | A |
5728131 | Frantzen et al. | Mar 1998 | A |
5749894 | Engelson | May 1998 | A |
5752974 | Rhee et al. | May 1998 | A |
5766160 | Samson et al. | Jun 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5779672 | Dormandy | Jul 1998 | A |
5785679 | Abolfathi et al. | Jul 1998 | A |
5795331 | Cragg et al. | Aug 1998 | A |
5800526 | Anderson et al. | Sep 1998 | A |
5823198 | Jones et al. | Oct 1998 | A |
5824037 | Fogarty et al. | Oct 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5830230 | Berryman et al. | Nov 1998 | A |
5843160 | Rhodes | Dec 1998 | A |
5861003 | Latson et al. | Jan 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5916235 | Guglielmi | Jun 1999 | A |
5925059 | Palermo et al. | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5935145 | Villar et al. | Aug 1999 | A |
5944733 | Engelson | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5980514 | Kupiecki et al. | Nov 1999 | A |
5984963 | Ryan et al. | Nov 1999 | A |
6015424 | Rosenbluth et al. | Jan 2000 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6024754 | Engelson | Feb 2000 | A |
6059823 | Holman et al. | May 2000 | A |
6063121 | Xavier et al. | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6080194 | Pachence et al. | Jun 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096021 | Helm et al. | Aug 2000 | A |
6102940 | Robichon et al. | Aug 2000 | A |
6110198 | Fogarty et al. | Aug 2000 | A |
6113629 | Ken | Sep 2000 | A |
6136015 | Kurz et al. | Oct 2000 | A |
6139520 | McCrory et al. | Oct 2000 | A |
6146373 | Cragg et al. | Nov 2000 | A |
6149664 | Kurz | Nov 2000 | A |
6152956 | Pierce | Nov 2000 | A |
6165193 | Greene, Jr. et al. | Dec 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6193745 | Fogarty et al. | Feb 2001 | B1 |
6196230 | Hall et al. | Mar 2001 | B1 |
6203550 | Olson | Mar 2001 | B1 |
6203779 | Ricci et al. | Mar 2001 | B1 |
6214036 | Letendre et al. | Apr 2001 | B1 |
6231562 | Khosravi et al. | May 2001 | B1 |
6238403 | Greene, Jr. et al. | May 2001 | B1 |
6248122 | Klumb et al. | Jun 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6273909 | Kugler et al. | Aug 2001 | B1 |
6273917 | Inoue | Aug 2001 | B1 |
6283991 | Cox et al. | Sep 2001 | B1 |
6287315 | Wijeratne et al. | Sep 2001 | B1 |
6287335 | Drasler et al. | Sep 2001 | B1 |
6290731 | Solovay et al. | Sep 2001 | B1 |
6293960 | Ken | Sep 2001 | B1 |
6296603 | Turnlund et al. | Oct 2001 | B1 |
6296604 | Garibaldi et al. | Oct 2001 | B1 |
6299597 | Buscemi et al. | Oct 2001 | B1 |
6299619 | Greene, Jr. et al. | Oct 2001 | B1 |
6312421 | Boock | Nov 2001 | B1 |
6312462 | McDermott et al. | Nov 2001 | B1 |
6312463 | Rourke et al. | Nov 2001 | B1 |
6315709 | Garibaldi et al. | Nov 2001 | B1 |
6319276 | Holman et al. | Nov 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6331184 | Abrams | Dec 2001 | B1 |
6334869 | Leonhardt et al. | Jan 2002 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6344056 | Dehdashtian | Feb 2002 | B1 |
6350270 | Roue | Feb 2002 | B1 |
6358556 | Ding et al. | Mar 2002 | B1 |
6361556 | Chuter | Mar 2002 | B1 |
6364823 | Garibaldi et al. | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6375669 | Rosenbluth et al. | Apr 2002 | B1 |
6379329 | Naglreiter et al. | Apr 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6395019 | Chobotov | May 2002 | B2 |
6409757 | Trout, III et al. | Jun 2002 | B1 |
6458119 | Berenstein et al. | Oct 2002 | B1 |
6463317 | Kucharczyk et al. | Oct 2002 | B1 |
6486510 | Camrud et al. | Nov 2002 | B2 |
6494889 | Fleischman et al. | Dec 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6521244 | Kanesaka | Feb 2003 | B1 |
6527739 | Bigus et al. | Mar 2003 | B1 |
6544219 | Happ et al. | Apr 2003 | B2 |
6544276 | Azizi | Apr 2003 | B1 |
6551280 | Knighton et al. | Apr 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6558367 | Cragg et al. | May 2003 | B1 |
6565602 | Rolando et al. | May 2003 | B2 |
6585756 | Strecker | Jul 2003 | B1 |
6585760 | Fogarty | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6613037 | Khosravi et al. | Sep 2003 | B2 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6616684 | Vidlund et al. | Sep 2003 | B1 |
6626928 | Raymond et al. | Sep 2003 | B1 |
6626938 | Butaric et al. | Sep 2003 | B1 |
6629947 | Sahatjian et al. | Oct 2003 | B1 |
6645167 | Whalen, II et al. | Nov 2003 | B1 |
6656214 | Fogarty et al. | Dec 2003 | B1 |
6663607 | Saikeu et al. | Dec 2003 | B2 |
6663667 | Dehdashtian et al. | Dec 2003 | B2 |
6692510 | West | Feb 2004 | B2 |
6695876 | Marotta et al. | Feb 2004 | B1 |
6712826 | Lui | Mar 2004 | B2 |
6723108 | Jones et al. | Apr 2004 | B1 |
6729356 | Baker et al. | May 2004 | B1 |
6730119 | Smalling | May 2004 | B1 |
6764510 | Vidlund et al. | Jul 2004 | B2 |
6827735 | Greenberg | Dec 2004 | B2 |
6843803 | Ryan et al. | Jan 2005 | B2 |
6852097 | Fulton, III | Feb 2005 | B1 |
6921410 | Porter | Jul 2005 | B2 |
7011676 | Dong | Mar 2006 | B2 |
7070609 | West | Jul 2006 | B2 |
7070616 | Majercak et al. | Jul 2006 | B2 |
7081129 | Chobotov | Jul 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7128736 | Abrams et al. | Oct 2006 | B1 |
7147660 | Chobotov et al. | Dec 2006 | B2 |
7147661 | Chobotov et al. | Dec 2006 | B2 |
7530988 | Evans et al. | May 2009 | B2 |
7615071 | Chobotov | Nov 2009 | B2 |
7708771 | Chuter et al. | May 2010 | B2 |
8231665 | Kim et al. | Jul 2012 | B2 |
8231666 | Kim et al. | Jul 2012 | B2 |
8262686 | Fogarty et al. | Sep 2012 | B2 |
8361136 | Chobotov | Jan 2013 | B2 |
8535367 | Kim et al. | Sep 2013 | B2 |
8562662 | Kim et al. | Oct 2013 | B2 |
8647377 | Kim et al. | Feb 2014 | B2 |
8801769 | Chobotov | Aug 2014 | B2 |
8936633 | Kim et al. | Jan 2015 | B2 |
9295569 | Kim et al. | Mar 2016 | B2 |
9561037 | Fogarty et al. | Feb 2017 | B2 |
9561096 | Kim et al. | Feb 2017 | B2 |
9561097 | Kim et al. | Feb 2017 | B1 |
9615912 | Fogarty et al. | Apr 2017 | B2 |
9629636 | Fogarty et al. | Apr 2017 | B2 |
9750504 | Fogarty et al. | Sep 2017 | B2 |
9913651 | Fogarty et al. | Mar 2018 | B2 |
10383636 | Fogarty et al. | Aug 2019 | B2 |
10470868 | Kim et al. | Nov 2019 | B2 |
10470869 | Kim et al. | Nov 2019 | B2 |
20010020184 | Dehdashtian et al. | Sep 2001 | A1 |
20010044621 | Klumb et al. | Nov 2001 | A1 |
20010047202 | Slaikeu et al. | Nov 2001 | A1 |
20020019665 | Dehdashtian et al. | Feb 2002 | A1 |
20020026217 | Baker et al. | Feb 2002 | A1 |
20020045848 | Jaafar et al. | Apr 2002 | A1 |
20020052643 | Wholey et al. | May 2002 | A1 |
20020058986 | Landau et al. | May 2002 | A1 |
20020065542 | Lax et al. | May 2002 | A1 |
20020077693 | Barclay et al. | Jun 2002 | A1 |
20020082638 | Porter et al. | Jun 2002 | A1 |
20020082682 | Barclay et al. | Jun 2002 | A1 |
20020099441 | Dehdashtian | Jul 2002 | A1 |
20020107565 | Greenhalgh | Aug 2002 | A1 |
20020151957 | Kerr | Oct 2002 | A1 |
20020169497 | Wholey et al. | Nov 2002 | A1 |
20020183841 | Cohn et al. | Dec 2002 | A1 |
20020193821 | Trout | Dec 2002 | A1 |
20030004531 | Jones et al. | Jan 2003 | A1 |
20030014075 | Rosenbluth et al. | Jan 2003 | A1 |
20030028209 | Teoh et al. | Feb 2003 | A1 |
20030051735 | Pavcnik et al. | Mar 2003 | A1 |
20030074017 | Shah | Apr 2003 | A1 |
20030130724 | DePalma et al. | Jul 2003 | A1 |
20030171805 | Berg et al. | Sep 2003 | A1 |
20030195607 | Trout et al. | Oct 2003 | A1 |
20030204246 | Chu et al. | Oct 2003 | A1 |
20030216802 | Chobotov | Nov 2003 | A1 |
20030220666 | Mirigian et al. | Nov 2003 | A1 |
20030220667 | van der Burg et al. | Nov 2003 | A1 |
20030229286 | Lenker | Dec 2003 | A1 |
20040044358 | Khosravi et al. | Mar 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040073190 | Deem et al. | Apr 2004 | A1 |
20040073288 | Kerr | Apr 2004 | A1 |
20040098027 | Teoh et al. | May 2004 | A1 |
20040116997 | Taylor et al. | Jun 2004 | A1 |
20040186556 | Hogendijk et al. | Sep 2004 | A1 |
20040210249 | Fogarty et al. | Oct 2004 | A1 |
20040254625 | Stephens et al. | Dec 2004 | A1 |
20050249776 | Chen et al. | Nov 2005 | A1 |
20060292206 | Kim et al. | Dec 2006 | A1 |
20070050008 | Kim et al. | Mar 2007 | A1 |
20070055355 | Kim et al. | Mar 2007 | A1 |
20070061005 | Kim et al. | Mar 2007 | A1 |
20080275536 | Zarins et al. | Nov 2008 | A1 |
20120179192 | Fogarty et al. | Jul 2012 | A1 |
20120265287 | Sharma et al. | Oct 2012 | A1 |
20120330343 | Kim et al. | Dec 2012 | A1 |
20130060320 | Fogarty et al. | Mar 2013 | A1 |
20140081374 | Kim et al. | Mar 2014 | A1 |
20140088690 | Fogarty et al. | Mar 2014 | A1 |
20140142685 | Kim et al. | May 2014 | A1 |
20170020653 | Kim et al. | Jan 2017 | A1 |
20170020654 | Fogarty et al. | Jan 2017 | A1 |
20170086853 | Fogarty et al. | Mar 2017 | A1 |
20170333047 | Fogarty et al. | Nov 2017 | A1 |
20180199946 | Fogarty et al. | Jul 2018 | A1 |
20190321051 | Fogarty et al. | Oct 2019 | A1 |
20200022801 | Kim et al. | Jan 2020 | A1 |
20200022802 | Kim et al. | Jan 2020 | A1 |
Number | Date | Country |
---|---|---|
2003204493 | Dec 2003 | AU |
2689388 | Oct 1993 | FR |
WO 1999016384 | Apr 1999 | WO |
WO 1999043273 | Sep 1999 | WO |
WO 1999065418 | Dec 1999 | WO |
WO 2000069367 | Nov 2000 | WO |
WO 2001006950 | Feb 2001 | WO |
WO 2001028434 | Apr 2001 | WO |
WO 2001093920 | Dec 2001 | WO |
WO 200202282 | Dec 2002 | WO |
WO 2004045393 | Jun 2004 | WO |
Entry |
---|
FR 2689388—English Abstract. |
Franklin et al, “Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis,” Brit. J. Surgery, 86(6):771-775, 1999. |
Pyo et al, “Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms,” J. Clinical Investigation, 105(11):1641-1649, 2000. |
Tambiah et al, “Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae,” Brit. J. Surgery: 88(7):935-940, 2001. |
Villareal et al, “Early Results Using Bare Metal Stents With or Without Coil Embolization for AAA Exclusion,” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 8 pages, 2001. |
Walton, et al, “Inhibition of Prostogiandin E2 Synthesis in Abdominal Aortic Aneurysms,” Circulation, pp. 48-54, Jul. 6, 1999. |
Xu et al, “Sp 1 increases Expression of Cyclooxygenase-2 in Hypoxic Vascuar Endothelium,” J. Biological Chemistry, 275(32):24583-24589, 2000. |
Number | Date | Country | |
---|---|---|---|
20170360553 A1 | Dec 2017 | US |
Number | Date | Country | |
---|---|---|---|
60447056 | Feb 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15284381 | Oct 2016 | US |
Child | 15670797 | US | |
Parent | 13666756 | Nov 2012 | US |
Child | 15284381 | US | |
Parent | 11351423 | Feb 2006 | US |
Child | 13666756 | US | |
Parent | 10778870 | Feb 2004 | US |
Child | 11351423 | US |